Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Vorolanib||Phase I||Actionable||In a Phase I trial, Vorolanib (X-82) was well tolerated and demonstrated preliminary efficacy, resulting in a complete response in 2% (1/49), a partial response in 2% (1/49), and stable disease in 51% (25/49) of patients with advanced solid tumors, with a median progression-free survival of 2 months (PMID: 30478190; NCT01296581).||30478190|